Drugs / doxifluridine
last change Mar 2010 re-read 2 minutes ago

doxifluridine

Small molecule targets TYMS via inhibition

Developed for
gastric adenocarcinoma · gastric cancer

Trials 0

Also used as a comparator or background therapy in 3 trials
PhaseRegistry idDatesIndicationSponsorStatusOutcome
Phase 32 trials
Phase 3 NCT00296335 Comparator Feb 2002 → Nov 2007 gastric adenocarcinoma Asan Medical Center Completed No outcome recorded
Phase 3 NCT00296322 Comparator Oct 2001 → Dec 2007 gastric cancer Asan Medical Center Completed No outcome recorded
Phase 41 trial
Phase 4 NCT01401075 Background Mar 2006 → Apr 2008 gastric cancer Abnoba GmbH Completed No outcome recorded

Evidence & citations 13 cited values

Every value below carries the sentence it was read from. 4 sources stand behind the page.

FieldValueCited text
Known as doxifluridine ClinicalTrials.gov intervention name — accepted as the source's own label NCT01401075
2

NCT00296322

NCT00296335

Known as 5'-deoxy-5-fluorouridine (5'-dfur) ChEMBL registry synonym — accepted as the source's own label CHEMBL1130
Known as Capecitabine related compound b ChEMBL registry synonym — accepted as the source's own label CHEMBL1130
Known as Doxifluridina ChEMBL registry synonym — accepted as the source's own label CHEMBL1130
Known as Flutron ChEMBL registry synonym — accepted as the source's own label CHEMBL1130
Known as Fulturon ChEMBL registry synonym — accepted as the source's own label CHEMBL1130
Known as Furtulon ChEMBL registry synonym — accepted as the source's own label CHEMBL1130
Known as NSC-758890 ChEMBL registry synonym — accepted as the source's own label CHEMBL1130
Known as RO 219738 ChEMBL registry synonym — accepted as the source's own label CHEMBL1130
Action Inhibit “Thymidylate synthase inhibitor” CHEMBL1130
Modality Small molecule CHEMBL1130
Route Oral “Doxifluridine 460-600mg/m2/day per oral for 3 months” NCT00296322
Target TYMS “Thymidylate synthase inhibitor” CHEMBL1130